A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_sessionrh6095v1amv5o6uekgsguo2p5bmel4sm): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

Memantine for treatment-resistant OCD. | LitMetric

Download full-text PDF

Source
http://dx.doi.org/10.1176/appi.ajp.162.11.2191-aDOI Listing

Publication Analysis

Top Keywords

memantine treatment-resistant
4
treatment-resistant ocd
4
memantine
1
ocd
1

Similar Publications

This case report discusses the use of intravenous (IV) ketamine as a potential therapeutic agent for early-onset dementia. A 56-year-old female with a diagnosis of early-onset dementia showed significant cognitive decline despite trying and failing several standard treatments such as memantine, donepezil, and rivastigmine. Given the promising results of ketamine in other neurological and psychiatric disorders, the patient underwent a series of IV ketamine infusions over a period of two months.

View Article and Find Full Text PDF

Pediatric Treatment-Resistant Obsessive Compulsive Disorder: Treatment Options and Challenges.

Paediatr Drugs

July 2024

Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, 1977 Butler Blvd, Suite 4-400, Houston, TX, 77030, USA.

Article Synopsis
  • Pediatric OCD is a serious mental health condition that can be hard to treat, and about 10% of kids don't get better with standard treatments.
  • Researchers looked at different ways to help those kids who don't respond to normal treatments, including learning from studies done on adults.
  • The most promising options for treating these kids include special intensive programs and using certain medications alongside antidepressants, but more research is needed to find the best solutions.
View Article and Find Full Text PDF

Clozapine is the only approved drug for treatment-resistant schizophrenia, but the response to the drug is often inadequate. Augmentation with other antipsychotics, anticonvulsants, and antidepressants is recommended for such patients, but there is a lack of evidence regarding the most effective therapy. This network meta-analysis was conducted to evaluate the efficacy of pharmacological agents used in the augmentation strategies in patients who were partial/ non-responders to clozapine.

View Article and Find Full Text PDF

Clinical Indications of Memantine in Psychiatry-Science or Art?

Psychopharmacol Bull

February 2023

Naguy, MBBch, MSc, Child/Adolescent Psychiatrist, Al-Manara CAP Centre, Kuwait Centre for Mental Health (KCMH), Jamal Abdul-Nassir St, Shuwaikh, State of Kuwait.

Background: Memenatine is USFDA approved for dementia of Alzheimer's disease. Apart from this indication, trend of its use in psychiatry is on the rise addressing a multitude of disorders.

Study Question: Memantine remains one of only few psychotropic drugs with antiglutamate activity.

View Article and Find Full Text PDF

The NMDA receptor antagonists memantine and ketamine as anti-migraine agents.

Naunyn Schmiedebergs Arch Pharmacol

July 2023

Department of Pediatric Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland.

Migraine is a debilitating disorder affecting females more frequently than males. There is some evidence that drugs targeting glutamate receptors: memantine and ketamine might be beneficial in the therapy of this entity. Therefore, the purpose of this work is to present NMDA receptor antagonists, memantine and ketamine, as potential anti-migraine agents.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!